NASDAQ: BNOX - Bionomics Limited

Lønnsomhet i seks måneder: -49.58%
Sektor: Healthcare

Kampanjeplan Bionomics Limited

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

flere detaljer
It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

EBITDA -0.0079
EV/EBITDA -0.3839
IPO date 2021-12-16
ISIN US09063M2052
Industry Biotechnology
P/BV 1.94
P/S 18.21
Sector Health Care
Валюта usd
Валюта отчета aud
Выручка 0.0052
Сайт https://www.bionomics.com.au
Цена ао 0.278
Число акций ао 0.00816 млрд
Prisendring per dag: -9.44% (4.45)
Prisendring per uke: +38.26% (2.9148)
Prisendring per måned: +12.7% (3.576)
Prisendring over 3 måneder: -47.51% (7.6776)
Prisendring over seks måneder: -49.58% (7.9932)
Prisendring per år: +172.3% (1.48)
Prisendring over 3 år: -68.64% (12.85)
Prisendring over 5 år: 0% (4.03)
Prisendring over 10 år: 0% (4.03)
Prisendring siden begynnelsen av året: +34.28% (3.0012)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 4290.29 1
P/BV 4.91 3
P/E 0 0
EV/EBITDA -7.47 0
Total: 2.75

Effektivitet

Navn Betydning Karakter
ROA, % -66284.99 0
ROE, % -117366.73 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.027 10
Total: 9.6

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % -99.32 0
Lønnsomhet Ebitda, % -88.49 0
Lønnsomhet EPS, % 2304445.45 10
Total: 4
Flere detaljer

Institusjoner Volum Dele, %
Lynx1 Capital Management Lp 824305 10.1
Point72 Asset Management, L.P. 331000 4.06
Morgan Stanley 94967 1.16
Two Sigma Investments, LP 31272 0.38
XTX Topco Ltd 11834 0.15
Tower Research Capital LLC (TRC) 1606 0.02
Rhumbline Advisers 505 0.01
UBS Group AG 329 0
Aspire Private Capital, LLC 200 0



Veileder Stillingstittel Betaling Fødselsår
Dr. Spyridon Papapetropoulos M.D., Ph.D. CEO, President & Director 510.37k 1973 (52 år)
Mr. Timothy M. Cunningham CPA, M.B.A. Chief Financial Officer N/A 1963 (62 år)
Dr. Julie Kerner Ph.D. Senior Vice President of Business Operations N/A
Ms. Elizabeth Doolin Senior Vice President of Clinical Development 1965 (60 år)
Dr. Mark A. Smith M.D., Ph.D. Chief Medical Officer 1955 (70 år)

Adresse: Australia, Eastwood, 200 Greenhill Road - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.bionomics.com.au